RAZID tablets are indicated for the treatment of: Active duodenal ulcer; Active benign gastric ulcer; Symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD); H. pylori-positive duodenal ulcers, as part of the eradication programme with appropriate antibiotics; Maintenance treatment of healed erosive or ulcerative GORD. Efficacy has not been demonstrated for periods exceeding 12 months.